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ABSTRACT 25 
Hyaluronic acid (HA) is physiologically synthesized by several human cells types but it is also a 26 
widespread ingredient of commercial products, from pharmaceuticals to cosmetics. Despite its 27 
extended use, the precise intra- and extra-cellular effects of HA at low-molecular-weight (LWM-HA) 28 
are currently unclear. At this regard, the aim of this study is to in-depth identify and quantify 29 
proteome’s changes in normal human dermal fibroblasts after 24 hours treatment with 0.125, 0.25 30 
and 0.50 % LMW-HA (20-50 kDa) respectively, vs controls. To do this, a label-free quantitative 31 
proteomic approach based on high-resolution mass spectrometry was used. Overall, 2328 proteins 32 
were identified of which 39 significantly altered by 0.125 %, 149 by 0.25 % and 496 by 0.50 % 33 
LMW-HA. Protein networking studies indicated that the biological effects involve the enhancement 34 
of intracellular activity at all concentrations, as well as the extracellular matrix reorganization, 35 
proteoglycans and collagen biosynthesis. Moreover, the cell’s wellness was confirmed, although mild 36 
inflammatory and immune responses were induced at the highest concentration. The more complete 37 
comprehension of intra- and extra-cellular effects of LMW-HA here provided by an advanced 38 
analytical approach and protein networking will be useful to further exploit its features and improve 39 
current formulations.  40 
 41 
Abbreviations: HA, hyaluronic acid; LMW-HA, low-molecular-weight hyaluronic acid; HMW-42 
HA, high-molecular-weight hyaluronic acid; nLC-HRMS, nano liquid chromatography- high 43 
resolution mass spectrometry 44 
 45 
Keywords: Low-molecular-weight hyaluronic acid; dermal fibroblasts; mass spectrometry; 46 
quantitative proteomics; networking 47 
 48 
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1. INTRODUCTION 50 
The extracellular environment, also referred as extracellular matrix (ECM), is principally formed by 51 
glycosaminoglycans involved in several biological functions mainly related to their molecular 52 
structure [1]. Among these, hyaluronic acid (HA), an unbranched glycosaminoglycan formed by 53 
repetitive disaccharide units of N-acetyl-D-glucosamine and D-glucuronic acid linked through 54 
alternating ß-1,3- and ß-1,4-glycosidic bonds, is synthesized in human by different haluronan 55 
synthase isoforms (HAS1, HAS2 and HAS3). Hyaluronidases (HYALs) and reactive oxygen species 56 
(ROS) are instead responsible for around 30% of its degradation. The remaining is systemically 57 
metabolized by endothelial cells of the lymphatic vessel and liver [2]. Because of the diverse degrees 58 
of physiological enzymatically and non-enzymatically polymerization, HA is usually classified as 59 
low-molecular-weight (LMW-HA) when ≤ 106 Da, or as high-molecular-weight (HMW-HA) when 60 
> 106 Da. Nevertheless, a precise cutoff is not defined. 61 
About biological functions, endogenous HMW-HA demonstrated a positive role in the control of 62 
tissue hydration, inflammatory and immune processes, tissue repair, and endothelial cellular growth 63 
[3, 4, 5]. On the other hand, endogenous LWM-HA may induce pro-inflammatory activity stimulating 64 
cytokines, chemokines and growth factors as well as the ECM remodeling, uncontrolled cellular 65 
growth, and angiogenesis during wound healing [3, 6]. Since last century, HA has been attracting the 66 
attention of many industrial fields, from pharmaceutical to cosmetic ones due to its widespread 67 
distribution in humans and its diversified physiochemical proprieties including biocompatibility, 68 
biodegradability, mucoadhesivity, viscoelasticity and hygroscopicity [7]. In cosmetics HA is widely 69 
used as anti-ageing especially for its ability to induce tissue boost, skin hydration and collagen 70 
stimulation [8]. Pavicic et al. [9] for example demonstrated that HMW-HA improves only hydration 71 
in aged skin probably because of its low skin penetration, while LMW-HA (50-800 kDa) shows better 72 
results on skin elasticity. Moreover, exogenous LWM-HA has showed to cross the corneum stratum 73 
[10, 11] and the epidermis [12] more easily than the HMW-HA, supporting its currently increasing 74 
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use in the topical formulations, although the detailed intra- and extra-cellular changes induced by 75 
exogenous LMW-HA are poorly described. The aim of this work is to quantitatively describe the 76 
proteome alterations induced by 20-50 kDa LMW-HA in normal human dermal fibroblasts by 77 
advanced mass spectrometric technique and network analysis. Indeed, the current development of 78 
‘omics sciences (genomics, proteomics, metabolomics etc.) supported by performing analytical tools 79 
is showing a new molecular panorama due to a huge amount of data available. To own our knowledge, 80 
this is the first proteomics study applied to exogenous 20-50 kDa LWM-HA to gain a deeper insight 81 
into its molecular effects at fibroblast level. Therefore, the results here obtained will allow reaching 82 
a more complete comprehension about biological processes influenced by 20-50 kDa LWM-HA, 83 
useful information for the improvement also of existing cosmetics formulations and for the 84 
optimization of personalized treatments. 85 
 86 
2.  MATERIAL AND METHODS 87 
2.1 Cell culture  88 
The adult normal human dermal fibroblasts (NHDF-Ad 28887; Lonza) were cultured as a monolayer 89 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) containing 10% FBS (Euroclone), 1% 90 
glutamine and 1% penicillin-streptomycin antibiotic (Lonza), at 37 °C in a humidified atmosphere of 91 
5% CO2.  92 
 93 
2.2 Cell viability assays  94 
The viability of cells was evaluated using MTT reduction assay (Sigma-Aldrich) and Real Time Glo-95 
MT kit assay (Promega). Briefly, 9x103 NHDF-Ad cells were seeded on a 96-well plate overnight. 96 
LMW-HA powder (RENOVHYAL 20-50 kDa; SOLIANCE – Pomacle, France) was dissolved in 97 
complete DMEM to obtain different concentrations (w/v): 0.125 %, 0.25 %, 0.50 %, 1.00 % and 2.50 98 
%. Each LMW-HA cell media solution was added to the cells. Treated and untreated cells, as control, 99 
were incubated in biological duplicate for 24 hours. For the viability cells’ assessment, the MTT and 100 
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RealTime Glo-MT assays were performed following the standard protocols. All statistical analyses 101 
were done by the GraphPad software (v 6.0). 102 
 103 
2.3 Cell treatment 104 
Three experimental conditions were planned considering the results of cell viability assays and the 105 
usual concentrations in the cosmetic products. NHDF-Ad (7th passage, 90% of confluence) seeded in 106 
T75 flasks were treated in biological duplicate with 0.125 %, 0.25 % and 0.5 % LMW-HA, w/v in 107 
cell media, respectively for 24 hours considering the physiological turn-over. Two untreated flasks 108 
were used as control. Whole experiment was replicate three times to increase the reliability of results.  109 
 110 
2.4 Sample preparation 111 
Once treated, all cells were trypsinized (Gibco) and pelleted by two cycle of centrifuge at 400 g, room 112 
temperature for 5 min. The whole protein was extracted by using a buffer composed by 8 M urea in 113 
50 mM Tris-HCl, 30 mM NaCl (Bio-Rad) at 8.5 pH and 1 % of protease inhibitor cocktail (Sigma-114 
Aldrich) followed by centrifugation at 14000 x g, 4° C for 30 min. The amount of proteins was 115 
quantified by the Bradford Reagent (Sigma-Aldrich) following the standard procedure. 20 µg of 116 
proteins in 50 mM NH₄HCO₃ were reduced with 5 mM DL-dithiothreitol (DTT, Sigma-Aldrich) for 117 
30 min at 52°C, then centrifuged at 500 rpm and alkylated with 15 mM iodoacetamide (Sigma-118 
Aldrich) for 20 min in the dark at room temperature. The trypsin digestion was performed in 1:20 119 
enzyme:protein ratio (w/w) (Trypsin Sequencing Grade; Roche, Monza, Italy) overnight at 37°C [13].  120 
 121 
2.5 High-resolution mass spectrometry analysis (nLC-HRMS)  122 
To increase the quality of instrumental analysis, the digested samples were further purified and 123 
concentrated by 0.2 µL C-18 resin ZipTip (Millipore, Milan, Italy). Tryptic peptides were analyzed 124 
using a Dionex Ultimate 3000 nano-LC system (Sunnyvale CA, USA) connected to Orbitrap 125 
Fusion™ Tribrid™ Mass Spectrometer (Thermo Scientific, Bremen, Germany) equipped with a 126 
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nano-electrospray ion source (nESI). Peptide mixtures were pre-concentrated onto an Acclaim 127 
PepMap 100 - 100 μm × 2 cm C18 and separated on EASY-Spray column, 25 cm × 75 μm ID packed 128 
with Thermo Scientific Acclaim PepMap RSLC C18, 3 μm, 100 Å. The temperature was set to 35 °C 129 
and the flow rate was 300 nL min−1. Mobile phases were the following: 0.1% formic acid (FA) in 130 
water (solvent A); 0.1% FA in water/acetonitrile with 2/8 ratio (solvent B). The elution gradient was 131 
from 96% buffer A to 40% buffer B for 110 min. MS spectra were collected over an m/z range of 132 
375-1500 Da at 120,000 resolutions, operating in data dependent scan mode, cycle time 3 sec between 133 
master scans. Higher-energy collision dissociation (HCD) was performed with collision energy set at 134 
35 eV in positive polarity. Each sample was analyzed in three technical replicates. 135 
 136 
2.6 Data analysis 137 
The instrumental raw files were analyzed by MaxQuant software v1.6.6.0 [14] set on 138 
Uniprot_Homosapiens database against the Andromeda search engine. The quantification of peptides 139 
and related proteins for each control and treated sample in biological duplicate and technical 140 
triplicates was based on the LFQ intensities. Trypsin as the digestive enzyme, variable modification 141 
of carbamidomethylation of cysteine (+57.021 Da), fixed modification of methionine oxidation 142 
(+15.995 Da), N-terminal acetylation (+42.011 Da) and LFQ minimum ratio count to 2 were set as 143 
further parameters. The interpretation and visualization of results from MaxQuant software were 144 
performed by a two-sample t-test using Perseus (v1.6.1.3, Max Planck Institute of Biochemistry, 145 
Germany). The protein variations (log2 fold changes) were evaluated by using (0.125 % LMW-HA 146 
vs control: 0.25 % LMW-HA vs control; 0.50 % LMW-HA vs control). Statistical parameters (p 147 
<0.05; q<0.05, q= FDR adjusted p-value) were set to identify the differentially expressed proteins 148 
between samples. The proteins were selected with a minimum of two peptides. Variability of 149 
biological replicates were measured using the scatter plot with Pearson correlation coefficient values 150 
of the LFQ intensities. The network protein analyses related to significantly altered proteins were 151 
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carried out by Reactome, STRING (v 11.0) and Ingenuity Pathways Analysis (last release; Qiagen) 152 
based on Gene Ontology database.  153 
  154 
3. RESULTS  155 
Considering the widespread use of HA in topical formulations and lack of deep knowledge about 156 
intra- and extra-cellular biological effects of LMW-HA, the goal of this study was to quantify the 157 
proteome’s changes induced by different concentrations of LMW-HA in normal human dermal 158 
fibroblasts.  159 
 160 
3.1 Treatments with LMW-HA: identification and differential proteomic analysis  161 
Based on the MTT and RealTime-Glo results (Figure 1) and the plausible exposition in the real 162 
setting, 0.125, 0.25 and 0.50 % LMW-HA were selected for the treatments. Automatic count of cells 163 
supported the cell viability results. After the treatment in biological duplicate with 0.125, 0.25 and 164 
0.50 % LWM-HA respectively, applying MS-based label-free quantitative (LFQ) proteomic analysis, 165 
a total of 2328 proteins were identified and quantified from treated and control samples. The quality 166 
and reproducibility of biological and technical replicates were confirmed by multi-scatter plot 167 
(Pearson coefficient values ≥ 0.98; Figure S1). As consequence of 0.125 % LWM-HA, 39 proteins 168 
resulted significantly altered (25 up-regulated, 14 down-regulated) (Figure 2a and Supplementary 169 
Table 1), 149 by 0.25 % LWM-HA (72 up-regulated, 77 down-regulated) (Figure 2b and 170 
Supplementary Table 1) and 496 by 0.50 % LWM-HA (334 up-regulated, 172 down-regulated) 171 
(Figure 2c and Supplementary Table 1). Moreover, some of these were affected by all LWM-HA 172 
concentrations tested (Figure S2 and Table 1) or by at least two out of three concentrations (Table 173 
1).  174 
  175 
3.2 Protein Network Analyses 176 
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After the identification and quantification of differentially regulated proteins, we applied protein 177 
network analyses using String, Reactome and Ingenuity Pathways Analysis (IPA) based on Gene 178 
Ontology (GO) terms to describe functional protein modules and pathways. See the Supplementary 179 
Table 2 for the complete list.  180 
 181 
3.2.1 Proteome’s changes induced by 0.125 % LWM-HA  182 
This study demonstrated limited proteome’s changes related to 0.125 % LWM-HA. Nevertheless, 183 
despite the low number of significantly altered proteins compared to controls (n=39; Supplementary 184 
Table 1), we mainly showed a noticeable increase of intracellular reorganization and mitochondrial 185 
activity (Supplementary Table 2). In details, we found a pronounced overexpression of organelle 186 
(FDR= 0.023) and mitochondrial matrix (FDR = 3.2 e-04) reorganization. The low number of down-187 
regulated proteins (n=14) did not allow us the identification of relevant nodes.  188 
 189 
3.2.2 Proteome’s changes induced by 0.25 % LWM-HA  190 
By increasing the concentration of LWM-HA from 0.125 to 0.25 % a more robust biological effect 191 
was observed with the significant alteration of 149 proteins (Table 1 and Supplementary Table 1) 192 
involved both in intra- and extra-cellular environment.  193 
Regarding the intracellular activity, we observed the up-regulation of several pathways such as 194 
chromosome organization (FDR = 0.0046) and oxidation-reduction process (FDR = 0.0437) (Figure 195 
3) but also cellular component organization or biogenesis involving 40 genes (FDR = 1.8 e-04), and 196 
protein processing (FDR = 0.040). More interesting were the LWM-HA effects outside the cell by 197 
raising the expression of proteins involved in collagen binding (FDR = 0.0266) and extracellular 198 
matrix organization (FDR = 0.0046) (Figure 3), elastic fibers formation (FDR = 0.03) or syndecans 199 
interactions (FDR = 0.014). ECM proteoglycans biosynthesis was also enriched (FDR = 0.015) 200 
especially for dermatan sulfate (HSPG2; fold change = 9.74) and chondroitin sulfate (CSPG4; fold 201 
change = 1.73). Conversely, a reduced expression of several immune pathways such as IL-12 202 
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signaling (FDR = 9.92 e-07) and neutrophil degranulation (FDR= 0.123) was observed, suggesting a 203 
great cells’ wellness when exposed to the medium concentration (0.25 % LWM-HA) (Table 1 and 204 
Supplementary Table 2).  205 
 206 
3.2.3 Proteome’s changes induced by 0.50 % LWM-HA  207 
The main intra- and extracellular impact was shown in cells treated with 0.50 % LWM-HA: we found 208 
in fact the highest number of significantly altered proteins, 496 vs 149 and 36 with 0.125 and 0.25 % 209 
LWM-HA, respectively, and related pathways. The intracellular effects were mainly supported by an 210 
increasing of cells’ proliferation by translation process (FDR = 6.02 e-11), of oxidation-reduction 211 
process (FDR = 7.75 e-06) and of immune process (FDR = 4.4 e-04) (Figure 4a). More in details, 212 
cells growth was demonstrated by enhancing of VEGFA-VEGFR2 complex (p value= 3.35 e-03), of 213 
RNA expression (p value = 6.72 e-05) and fibroblasts proliferation pathway (p value = 7.50 e-03) 214 
(Figure 4b). Furthermore, mitochondrial activity by acid citric cycle II (p value = 1.89 e-04), EIF2 215 
pathway (p value= 9.34 e-05) and Wnt signaling (FDR = 0.076) were also increased. In addition, 0.50 216 
% LWM-HA seemed to provide an increasing immune response by an up-regulation of IL-12 family 217 
signaling (FDR= 1.04 e-05) (Figure 4a) as well as IL2 (p value = 3.21 e-03; z score = 1.342), IL4 (p 218 
value = 6.91 e-03; z score = 1.633) and TNF signaling (p value = 2.73 e-01; z score = 1.788) (Figure 219 
4c).  In addition, also IL-1 family signaling (FDR = 3.72 e-04), NF-kB pathway (FDR = 2.15 e-05), 220 
and neutrophil degranulation (FDR = 0.007) showed an increasing vs control. Finally, in line with the 221 
previous concentration we observed a pronounced extracellular activity by an over-expression of 222 
HSPG2 (fold change = 8.15), FN1 (fold change = 3.18) and CPSG4 (fold change = 1.77) suggesting 223 
a high ECM reorganization mainly based on proteoglycans biosynthesis (Table 1 and 224 
Supplementary Table 2). 225 
 226 
4. DISCUSSION 227 
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A deepening knowledge of molecular effects induced by any active principle is fundamental to 228 
support its use, due to demonstration of safety and efficacy. Although the general attention was 229 
mainly focused on the intracellular environment, an increasing number of evidences has pointed out 230 
the biological importance also of the extracellular one. Indeed, the extracellular matrix (ECM) has 231 
showed to be involved in several physiological and pathological pathways [1]. High-molecular-232 
weight hyaluronic acid (HWM-HA) is one of the major ECM’s constituents, but also a widespread 233 
commercial ingredient for its superficial hydration proprieties. More recently, LMW-HA became 234 
commercially available especially for anti-aging use [8]. Despite its diffusion, the detailed intra- and 235 
extra- cellular impact of commercially available low-molecular-weight HA (LMW-HA) is not yet 236 
defined. At this regard, the objective of this study was to describe and quantify the proteins profile’s 237 
change induced by different concentrations of 20-50 kDa LWM-HA (0.125 %, 0.25 % and 0.50 % 238 
respectively) on normal human dermal fibroblasts. To do this, a quantitative proteomics approach 239 
was applied considering the large number of molecular information available by omics science, 240 
including proteomics, and the currently improvement of instrumental technique. The high-resolution 241 
mass spectrometric technique coupled with nano-LC was used and the results were explained by 242 
network and pathways analyses. In line with previous evidences [3, 6] but in a deeper way, here we 243 
demonstrated both an intra- and extra-cellular impact of 20-50 kDa LWM-HA. Indeed, the 24 hours 244 
treatment with LWM-HA induced, for example, an increasing of cell proliferation and growth as well 245 
as of extracellular matrix reorganization or proteoglycans biosynthesis. Moreover, at the highest 246 
concentration (0.50 %) the inflammatory and immune responses were activated, among all, by the 247 
stimulation of lymphocytes, interleukins (IL-12, IL-1, IL-2, IL-4 etc.) or necrosis tumor factor 248 
signaling. However, the global cells’ wellness was still sustained as demonstrated, for example, by 249 
the significant up-regulation of EIF2 pathway implicated in the protein synthesis, of citrate acid cycle 250 
that is a pivotal factor of mitochondrial functionality and of fibroblasts proliferation. In addition, 0.50 251 
% LWM-HA enhanced the VEGFA-VEGFR2 signaling that is actively involved in angiogenesis by 252 
inducing the proliferation, survival and migration of endothelial cells, and by increasing endothelial 253 
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permeability [15, 16]. As further confirmation of the cells’ viability and ECM reorganization after 254 
the 0.25 and 0.50 % LMW-HA treatment, a significant upregulation was demonstrated by FN1, 255 
HSPG2 and EMILIN 1 genes. FN1 encodes for fibronectin, a glycoprotein of the extracellular matrix 256 
that plays a key role in cell adhesion and migration processes as well as in wound healing binding 257 
membrane-spanning receptor proteins as integrins but also collagen, fibrin, and heparan sulfate 258 
proteoglycans (i.e. syndecans, gypicans and perlecans) [17, 18]. Then, HSPG2 encodes exactly for 259 
heparan sulfate proteoglycans (HSPGs) that show angiogenic and growth-promoting attributes 260 
primarily by acting as a coreceptor for basic fibroblast growth factor (FGF2) [19, 20] as well as a 261 
cross-linker among many extracellular matrix components and cell-surface molecules (laminin, 262 
prolargin, collagen type IV etc.). Additionally, as resulted also in this study, HSPGs demonstrated a 263 
pivotal role in regulating developmental signaling pathways including transforming growth factor-β 264 
or β-catenin independent Wnt signaling [17], where Wnt are lipid-modified proteins strictly 265 
associated with cell surface and ECM. EMILIN 1, a multidomain glycoprotein, is also involved in 266 
skin wound reparation and in control of cell proliferation, in the matrix anchoring fibroblast to 267 
keratinocytes [20]. 268 
This study has strong points and limitations. The first include: i) the analytical instruments and the 269 
applied methodology, that allowed us a detailed and quantified description of a huge number of 270 
proteins; ii) the investigation of less known form of HA (i.e. LMW-HA); iii) the network analysis 271 
conducted by several software, which allowed to depict a complete intra- and extra-cellular overview; 272 
iv) the primary and healthy selected cell line; v) the LMW-HA concentrations tested that reflected 273 
those commonly used. With regard to the main limitations, it should be noted that a simple in vitro 274 
environment like that of cells, less complex that whole skin, could offer a limited view of the 275 
biological effects of a compound.  276 
In conclusion, treating normal human dermal fibroblast with hyaluronic acid at low-molecular-weight 277 
resulted in positive intra- and extra-cellular effects enhancing the nucleus and mitochondria 278 
functionality as well as the ECM reorganization. In addition, the inflammatory and immune activity 279 
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induced by the highest concentration seemed to be well tolerated. As next step, considering the close 280 
connection between proteins and other metabolites, also the lipidome profile’s changes will be 281 
analyzed to provide a more complete comprehension about the in vitro molecular effects of LWM-282 
HA supporting and improving its commercial use and safety.      283 
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 358 
Figure Legends 359 
Figure 1. Cell viability assays. a) MTT and b) RealTime Glo with LWM-HA 0.125 %, 0.25 %, 0.50 360 
%, 1.00 % and 2.50 % respectively.  361 
Figure 2. Distribution of differentially regulated proteins with a) LWM-HA 0.125 %, b) LWM-HA 362 
0.25 % and c) LWM-HA 0.50 %. Green color indicates up-regulation (log2 fold change ≥ 0.6), red 363 
color represents down-regulation (log2 fold change ≤ -0.6); Scatter plots of log2 fold change on x-364 
axis against -log p-value on y-axis of significantly quantified proteins. 365 
Figure 3. Networking of up-regulated proteins by LMW-HA 0.25 % (String). In label some of the 366 
most interesting pathways significantly altered.  367 
Figure 4. a) Networking of up-regulated proteins by LMW-HA 0.50 % (String). In label, some of 368 
more interesting pathways significantly altered. b) Proliferation’s pathways enhanced by LMW-HA 369 
0.50 % (IPA) c) Pathways involved in immune response significantly altered by LWM-HA 0.50% 370 
(IPA). For b) and c) in red the increased genes, in green those decreased. The color intensity is positive 371 
related to the up- or down-gene’s regulation; orange line leads to activation, yellow lines for findings 372 
inconsistent with state of downstream molecule; grey line for effect not predicted.   373 
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 374 
Supplementary figure legends 375 
Figure S1. Variabilities of biological replicates measured using the scatter plot (Perseus software) 376 
with Pearson correlation coefficient values of the LFQ intensities.  377 
Figure S2. Different expression of proteins significantly altered by LWM-HA 0.125 % (1st column, 378 
blue), LWM-HA 0.25% (2nd column, orange) and LWM-HA 0.50 % (3th column, grey) respectively. 379 
On x-axis, the list of gene names while on y-axis the log2 fold change (difference) of treated sample 380 
vs control.  381 
 382 
Table Legend 383 
Table 1. Some of differentially regulated proteins by LWM-HA concentrations (0.125 %, 0.25 % and 384 
0.50 %, respectively). In bold those more relevant for the networking explanation.  385 
 386 
Supplementary table legends 387 
Table S1. Complete list of identified proteins (Perseus). Among these, those significant for each 388 
concentration of LWM-HA (0.125%, 0.25% and 0.50%).  389 
Table S2. Complete list of significantly altered pathways for each concentration of LWM-HA 390 
(0.125%, 0.25% and 0.50%) provided by String and Reactome software, respectively.  391 
 392 
Table 1. 393 
Accession 
numbers 
Protein name Gene Name T0.125% 
vs C 
T0.25% 
vs C 
T0.50% 
vs C 
Q2L6I2 ATP-binding cassette sub-family F 
member 1 
ABCF1 1.36 1.56 1.55 
Q9Y6K8 Adenylate kinase isoenzyme 5 AK5 0.73 0.76 0.71 
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Q53F35 Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
ANP32B 1.37 1.41 1.56 
A0A087WZT3 BolA-like protein 2 BOLA2 0.71 0.74 - 
A8K651 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1QBP 1.41 - 1.46 
Q6IAW5 Calumenin CALU 1.24 1.21 1.29 
C9JEZ4 Cdc42 effector protein 3 CDC42EP3 - 0.73 0.80 
Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 - 1.73 1.77 
Q5VTU3 Dynein light chain Tctex-type 1 DYNLT1 - 1.38 1.50 
P47813 Eukaryotic translation initiation 
factor 1A 
EIF1AX 1.57 1.52 1.46 
Q9Y6C2 EMILIN-1 EMILIN1 - 4.75 3.31 
A0A0A0MT60 Peptidyl-prolyl cis-trans 
isomerase;FK506-binding protein 15 
FKBP15 1.59 1.31 1.32 
A0A024R462 Fibronectin FN1 - 3.91 3.18 
Q53TX0 Glutaminase kidney isoform, 
mitochondrial 
GLS 1.39 - 1.51 
B2R6K4 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
GNB1 - 0.72 0.83 
F5GZQ3 Trifunctional enzyme subunit beta, 
mitochondrial 
HADHB 1.41 1.78 2.04 
P16401 Histone H1.5 HIST1H1B 1.90 3.01 2.33 
P16403 Histone H1.2 HIST1H1C 1.30 2.14 1.83 
Q8IUE6 Histone H2A type 2-B HIST2H2AB 2.11 1.87 - 
X6RGJ2 Heterochromatin protein 1-binding 
protein 3 
HP1BP3 1.44 1.63 1.56 
A0A0S2Z410 3-hydroxyacyl-CoA dehydrogenase 
type-2 
HSD17B10 1.34 1.40 1.67 
A0A024RAB6 Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
HSPG2 - 9.74 8.15 
B4DT20 MICOS complex subunit MIC60 IMMT - 1.23 1.70 
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B4DWZ7 LanC-like protein 2 LANCL2 - 0.72 0.82 
P30533 Alpha-2-macroglobulin receptor-
associated protein 
LRPAP1 - 0.77 0.84 
Q8IV28 Nidogen-2 NID2 - 2.17 1.77 
Q15113 Procollagen C-endopeptidase 
enhancer 1 
PCOLCE - 1.46 1.25 
B4DDC8 Protein phosphatase 1G PPM1G 1.26 1.29 1.48 
 394 
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